Findings

What do systematic reviews say?

370 questions · 377 findings · 26 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 103 · 27.3%GRADE not reported 11 · 2.9%Very low 98 · 26%Low 75 · 19.9%Moderate 68 · 18%High 22 · 5.8%

Cannabis cigarettes vs placebo

Serious adverse events · people with active UC

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabis cigarettes vs placebo

Withdrawals due to adverse events · people with active UC

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabidiol vs placebo

Clinical response at 10 weeks · people with active UC

Cannabidiol showed no clear difference in clinical response at 10 weeks compared with placebo (low certainty).

1 finding from 1 review

Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
RR 1.37 [0.59, 3.21]
1 study · 60 participants
Low

Cannabidiol vs placebo

CRP (mg/dL) at end of study · people with active UC

1 finding from 1 review

Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Moderate

Cannabidiol vs placebo

IBDQ at week 6 · people with active UC

1 finding from 1 review

Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 53 participants
Moderate

Cannabidiol vs placebo

Adverse events · people with active UC

Cannabidiol probably leads to higher adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
RR 1.28 [1.05, 1.56]
1 study · 60 participants
Moderate

Cannabidiol vs placebo

Serious adverse events · people with active UC

Cannabidiol showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
RR 0.15 [0.01, 2.83]
1 study · 60 participants
Low

Cannabidiol vs placebo

Withdrawals due to adverse events · people with active UC

Cannabidiol showed no clear difference in withdrawal due to adverse event compared with placebo (low certainty).

1 finding from 1 review

Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
RR 2.14 [0.83, 5.51]
1 study · 60 participants
Low

Cannabis cigarettes vs placebo

Clinical remission · people with active UC

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabis cigarettes vs placebo

Clinical response · people with active UC

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Azathioprine vs placebo

Failure to maintain remission · Patients with quiescent ulcerative colitis

Azathioprine may leads to lower failure to maintain remission compared with placebo (low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis 2016 · Cochrane Headline outcomes only
RR 0.68 [0.54, 0.86]
4 studies · 232 participants
Low

Intervention not reported

Acute pancreatitis · Patients with quiescent ulcerative colitis

It is very uncertain whether the intervention changes acute pancreatitis (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis 2016 · Cochrane Headline outcomes only
RR 4.13 [0.48, 35.48]
6 studies · 279 participants
Very low

Intervention not reported

Bone marrow suppression · Patients with quiescent ulcerative colitis

It is very uncertain whether the intervention changes bone marrow suppression (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis 2016 · Cochrane Headline outcomes only
RR 3.09 [0.64, 14.83]
5 studies · 257 participants
Very low

Azathioprine vs placebo

Any adverse events · Patients with quiescent ulcerative colitis

It is very uncertain whether azathioprine changes any adverse events compared with placebo (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis 2016 · Cochrane Headline outcomes only
RR 2.51 [0.82, 7.74]
4 studies · 232 participants
Very low

Azathioprine vs placebo

Withdrawals due to adverse events · Patients with quiescent ulcerative colitis

It is very uncertain whether azathioprine changes withdrawal due to adverse event compared with placebo (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis 2016 · Cochrane Headline outcomes only
RR 7 [0.38, 128.87]
3 studies · 152 participants
Very low

Azathioprine vs sulfasalazine

Failure to maintain remission · Patients with quiescent ulcerative colitis

It is very uncertain whether azathioprine changes failure to maintain remission compared with sulfasalazine (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis 2016 · Cochrane Headline outcomes only
RR 1.52 [0.66, 3.5]
1 study · 25 participants
Very low

6‐Mercaptopurine vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Failure to maintain remission · Patients with quiescent ulcerative colitis

It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with 5‐ASA (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis 2016 · Cochrane Headline outcomes only
RR 0.53 [0.31, 0.9]
1 study · 22 participants
Very low

6‐Mercaptopurine vs methotrexate

Failure to maintain remission · Patients with quiescent ulcerative colitis

It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with methotrexate (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis 2016 · Cochrane Headline outcomes only
RR 0.55 [0.31, 0.95]
1 study · 26 participants
Very low

Azathioprine vs cyclosporin of remission

Failure to maintain remission · Patients with quiescent ulcerative colitis

It is very uncertain whether azathioprine (AZA) changes failure to maintain remission compared with cyclosporin of remission (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis 2016 · Cochrane Headline outcomes only
RR 0.8 [0.33, 1.92]
1 study · 16 participants
Very low

Intervention not reported

Any adverse event · Patients with quiescent ulcerative colitis

It is very uncertain whether the intervention changes any adverse event (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis 2016 · Cochrane Headline outcomes only
RR 2.82 [0.99, 8.01]
5 studies · 257 participants
Very low